If there is trans-placental antibody transfer (COVID vaccine induced antibodies) from vaccinated pregnant mother to child in utero (to newborn), what are implications to newborn's INNATE immunity?

What would the highly specific, high antigen affinity vaccine induced maternal antibodies do to the low affinity, broadly protective natural INNATE antibodies in children? Suppress, subvert?

Dr. Geert Vanden Bossche (GVB) argues that the vaccine induced antibodies will outcompete the innate antibodes for the target antigen and thus the innate antibodies that are needed to bind to the virus and thus educate and train the immune system, will be subverted. The result will be the child being unable to initiate it’s immune system. The highly immature vaccine induced antibodies could bind yet do so weakly and do not sterilize the virus. The innate antibodies that could sterilize, are blocked from binding.

GVB:

‘Intra-pandemic vaccination of toddlers with non-replicating antibody-based vaccines targeted at ASLVI[1]- or ASLVD[2]-enabling glycosylated viruses prevents education of innate immune effector cells (NK cells).

Key message:

Antibody-based vaccines teach the immune system to produce high levels of antibodies that are directed against the surface protein that is responsible for initiation of viral infection. Due to their high specificity and strong binding capacity, these vaccinal antibodies (Abs) outcompete the child’s innate antibodies for binding to the virus[3]. This not only sidelines virus-neutralization by the natural innate immune system but also hampers the ability of innate antibodies to educate the innate immune system’s NK cells (Natural Killer cells) regarding NK cell recognition of (and appropriate response to) molecular self-mimicking patterns that are expressed on virus-infected host cells. This is particularly problematic when mass vaccination campaigns are conducted during a pandemic as those drive natural selection and dominant expansion of more infectious immune escape variants.

[1] ASLVI: Acute self-limiting viral infection

[2] ASLVD: Acute self-limiting viral disease

[3] For the purpose of this manuscript, ‘virus’ relates to an ASLVI- or ASLVD-enabling glycosylated virus’

SOURCE:

https://pubmed.ncbi.nlm.nih.gov/35802776/

SOURCE:

https://pubmed.ncbi.nlm.nih.gov/34740773/